Conference Coverage

TCT: Novel drug-coated stent bests bare-metal in patients at high bleeding risk

Publish date: October 14, 2015

 

AT TCT 2015

References

LEADERS FREE was underwritten by Biosensors International, maker of the BioFreedom stent. Dr. Urban and several of his coinvestigators disclosed relationships with device makers, including Edward Lifesciences, Terumo, Abbott Vascular, and Quest Medical.

wmcknight@frontlinemedcom.com

On Twitter @whitneymcknight

Pages

Recommended Reading

FDA approves first bioabsorbable-polymer stent
MDedge Cardiology
Endovascular treatment of acute IVC thrombosis found effective
MDedge Cardiology
TCT: Absorbable metal scaffold performs well in BIOSOLVE II
MDedge Cardiology
ESC: What’s the hottest recent advance in cardiology? And the winner is …
MDedge Cardiology
TCT: Absorb BVS meets pivotal U.S. noninferiority goal
MDedge Cardiology
TCT: Radial PCI access as effective as femoral at 1 year
MDedge Cardiology
TCT: Routine thrombectomy with PCI raises stroke risk 66% in STEMI patients
MDedge Cardiology
TCT: FFR-CT improved costs, quality of life in PLATFORM trial
MDedge Cardiology
TCT: Ranolazine fails to block angina after incomplete revascularization
MDedge Cardiology
TCT: No difference at 2 years between Absorb BVS and XIENCE
MDedge Cardiology

Related Articles